High priorities: sustainability & continual improvement LEARN MORE>
High priorities: sustainability & continual improvement
Actavis Completes Forest Laboratories Acquisition LEARN MORE>
Actavis Completes Forest Laboratories Acquisition
>Go!

R&D Sites

World-Class R&D Network Focused on Generics, Brands and Biosimilars

Actavis provides a strong commitment to R&D, with an exceptional investment of approximately $1.7 billion in 2015, focused on the strategic development of innovative and durable value-enhancing products within brands, generics, biologics and OTC portfolios.

The Company has more than 20 innovative products in near- or mid-term development, and is strategically focused within its core therapeutic areas, with key candidates in Dermatology and Aesthetics, Eye Care, CNS, GI, Anti-infectives, Women’s Health and Urology.

The Company’s generics pipeline is also positioned to deliver sustainable growth, with approximately 230 Abbreviated New Drug Applications pending at FDA, including approximately 70 first-to-file applications, as well as nearly 1,000 marketing authorization applications filed outside of the U.S. in 2014.


Working at Actavis
Actavis is a dynamic, forward-thinking organization that offers exciting and unique opportunities at all levels across our Company.